Acceleration of drug development: A collaboration of many stakeholders

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 6, 2013, Pages 455-459

  Reynolds, K S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC RESEARCH; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG DEVELOPMENT; DRUG EXPOSURE; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; INVESTMENT; LAW; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REVIEW;

COOPERATIVE BEHAVIOR; DRUG DISCOVERY; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84878240261     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.63     Document Type: Review

References (13)

1. Milligan, P.A. et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin. Pharmacol. Ther. 93, 502-514 (2013).
2. Lalonde, R.L. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007).
3. Sheiner, L.B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61, 275-291 (1997).
4. Zineh, I. & Woodcock, J. Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation. Clin. Pharmacol. Ther. 93, 515-525 (2013).
5. US Congress. Food and Drug Administration Safety and Innovation Act (FDASIA) (S. 3187) 〈http://www.gpo.gov/fdsys/pkg/BILLS-112s3187enr/pdf/ BILLS-112s3187enr.pdf〉 (9 July 2012).
6. Throckmorton, D.C. CDER priorities 2012.
7. Presentation at FDA/CMS Summit 〈http://www.fda.gov/downloads/ AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM331455. pdf〉 (10 December 2012).
8. US Food and Drug Administration. Press release. New FDA task force will support innovation in antibacterial drug development 〈http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm320643.htm〉 (24 September 2012).
9. Rex, J.H. et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Inf. Dis. 13, 269-275 (2013).
10. Owen, R.P., Jain, L., Zhang, L. & Zineh, I. Office of Clinical Pharmacology Science Day: a forum to stimulate innovation in clinical pharmacology. Clin. Pharmacol. Ther. 93, 471-473 (2013).
11. Wagner, J.A. Accelerating biomedical research through open knowledge creation and stewardship. Clin. Pharmacol. Ther. 93, 476-478 (2013).
12. Breitstein, J. & Spigelman, M. The role of product development partnerships in advancing the development of drugs for unmet needs. Clin. Pharmacol. Ther. 93, 468-470 (2013).
13. DiFrancesco, R. et al. Clinical pharmacology quality assurance for HIV and related infectious diseases research. Clin. Pharmacol. Ther. 93, 479-482 (2013).